SU5205 is primarily used in research settings as a potent and selective inhibitor of histone deacetylases (HDACs), particularly HDAC1 and HDAC3. Its main application lies in oncology research, where it helps investigate the role of HDAC activity in cancer cell proliferation, apoptosis, and differentiation. By modulating gene expression through histone acetylation, SU5205 has shown potential in inducing cell cycle arrest and promoting the death of tumor cells in various cancer models. It is also employed to study epigenetic regulation in diseases beyond cancer, including neurodegenerative disorders and inflammatory conditions. Due to its ability to cross cell membranes effectively, SU5205 is valuable in cellular assays and in vivo studies aimed at understanding the therapeutic impact of HDAC inhibition. Its use remains confined to preclinical research, serving as a tool compound for validating HDAC-targeted therapies and screening for novel anticancer agents.